PNPLA3 and metabolic dysfunction-associated steatotic liver disease: No statistically significant results were found between miRNA‐122 levels and participants with NAFLD compare to control group (P = .090). No significant results were found between patient and control group for PNPLA3 I148M polymorphism (P = .087).